Difference between revisions of "P16"
Jump to navigation
Jump to search
(→Positive: more) |
(→Benign) |
||
Line 49: | Line 49: | ||
===Benign=== | ===Benign=== | ||
*p16 endometrial tubal metaplasia.<ref name=pmid17429140>{{Cite journal | last1 = Horree | first1 = N. | last2 = Heintz | first2 = AP. | last3 = Sie-Go | first3 = DM. | last4 = van Diest | first4 = PJ. | title = p16 is consistently expressed in endometrial tubal metaplasia. | journal = Cell Oncol | volume = 29 | issue = 1 | pages = 37-45 | month = | year = 2007 | doi = | PMID = 17429140 }}</ref> | *p16 endometrial tubal metaplasia.<ref name=pmid17429140>{{Cite journal | last1 = Horree | first1 = N. | last2 = Heintz | first2 = AP. | last3 = Sie-Go | first3 = DM. | last4 = van Diest | first4 = PJ. | title = p16 is consistently expressed in endometrial tubal metaplasia. | journal = Cell Oncol | volume = 29 | issue = 1 | pages = 37-45 | month = | year = 2007 | doi = | PMID = 17429140 }}</ref> | ||
* | |||
====Focal staining==== | |||
*[[Endometriosis]] - focal/weak staining may be seen.<ref name=pmid26095917>{{Cite journal | last1 = Stewart | first1 = CJ. | last2 = Bharat | first2 = C. | title = Clinicopathological and immunohistological features of polypoid endometriosis. | journal = Histopathology | volume = 68 | issue = 3 | pages = 398-404 | month = Feb | year = 2016 | doi = 10.1111/his.12755 | PMID = 26095917 }}</ref><ref name=pmid16462152>{{Cite journal | last1 = O'Neill | first1 = CJ. | last2 = McCluggage | first2 = WG. | title = p16 expression in the female genital tract and its value in diagnosis. | journal = Adv Anat Pathol | volume = 13 | issue = 1 | pages = 8-15 | month = Jan | year = 2006 | doi = 10.1097/01.pap.0000201828.92719.f3 | PMID = 16462152 }}</ref> | |||
==Negative== | ==Negative== |
Revision as of 16:48, 5 March 2017
P16 | |
---|---|
Immunostain in short | |
HSIL showing the characteristic p16 staining. (WC/Nephron) | |
Similar stains | HPV |
Use | HSIL versus LSIL, HPV associated SCC versus non-HPV associated SCC |
Subspeciality | gynecologic pathology, head and neck pathology |
Normal staining pattern | nuclear and cytoplasmic |
Positive | endometrial tubal metaplasia, cervical SCC, HPV-associated head and neck SCC, serous carcinoma of the endometrium |
p16 is a commonly used immunostain. It can be considered a surrogate marker for HPV infection. p16, like most other "p" stains, is a nuclear stain.
Pattern
- Nuclear stain +/- cytoplasmic staining.
Use
- Squamous lesions of the uterine cervix - see HSIL.
- Head and neck squamous cell carcinoma, specifically human papillomavirus-associated head and neck squamous cell carcinoma.
Head and neck squamous cell carcinoma
p16 testing is useful in:
- Lymph node metastases with an unknown primary - positivity suggests an oropharyngeal primary.
- Oropharyngeal carcinomas.
Note:
- Like elsewhere, i.e. other anatomical sites, p16 is an imperfect surrogate marker for the presence of HPV.[1]
- Non-oropharyngeal sites (oral cavity, larynx, and hypopharynx) are not well-studied; however, it is known that p16 positivity is much less common in there.[1]
Images
Positive
- Squamous cell carcinoma - esp. cervical SCC, anal SCC, penile SCC, HPV-associated head and neck SCC.
- High grade urothelial carcinoma ~86% of cases by PCR.[2]
- Serous carcinoma of the endometrium - should be strong.[3]
- High-grade squamous intraepithelial lesion - full thickness, strong.
- A subset of LSIL stains with p16; however, it is not full thickness - see HSIL article.
Benign
- p16 endometrial tubal metaplasia.[4]
Focal staining
- Endometriosis - focal/weak staining may be seen.[5][6]
Negative
References
- ↑ 1.0 1.1 Stephen, JK.; Divine, G.; Chen, KM.; Chitale, D.; Havard, S.; Worsham, MJ. (2013). "Significance of p16 in Site-specific HPV Positive and HPV Negative Head and Neck Squamous Cell Carcinoma.". Cancer Clin Oncol 2 (1): 51-61. doi:10.5539/cco.v2n1p51. PMID 23935769.
- ↑ Piaton, E.; Casalegno, JS.; Advenier, AS.; Decaussin-Petrucci, M.; Mege-Lechevallier, F.; Ruffion, A.; Mekki, Y. (Oct 2014). "p16(INK4a) overexpression is not linked to oncogenic human papillomaviruses in patients with high-grade urothelial cancer cells.". Cancer Cytopathol 122 (10): 760-9. doi:10.1002/cncy.21462. PMID 25069600.
- ↑ Chiesa-Vottero, AG.; Malpica, A.; Deavers, MT.; Broaddus, R.; Nuovo, GJ.; Silva, EG. (Jul 2007). "Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma.". Int J Gynecol Pathol 26 (3): 328-33. doi:10.1097/01.pgp.0000235065.31301.3e. PMID 17581420.
- ↑ Horree, N.; Heintz, AP.; Sie-Go, DM.; van Diest, PJ. (2007). "p16 is consistently expressed in endometrial tubal metaplasia.". Cell Oncol 29 (1): 37-45. PMID 17429140.
- ↑ Stewart, CJ.; Bharat, C. (Feb 2016). "Clinicopathological and immunohistological features of polypoid endometriosis.". Histopathology 68 (3): 398-404. doi:10.1111/his.12755. PMID 26095917.
- ↑ O'Neill, CJ.; McCluggage, WG. (Jan 2006). "p16 expression in the female genital tract and its value in diagnosis.". Adv Anat Pathol 13 (1): 8-15. doi:10.1097/01.pap.0000201828.92719.f3. PMID 16462152.
- ↑ Pereira, TC.; Share, SM.; Magalhães, AV.; Silverman, JF. (Jan 2011). "Can we tell the site of origin of metastatic squamous cell carcinoma? An immunohistochemical tissue microarray study of 194 cases.". Appl Immunohistochem Mol Morphol 19 (1): 10-4. doi:10.1097/PAI.0b013e3181ecaf1c. PMID 20823766.